FLT3 and acute myeloid leukemia: In one analysis of 243 patients >60 years of age with newly diagnosed AML with normal karyotype treated with intensive chemotherapy, the presence of a FLT3-ITD mutation was associated with shorter disease-free survival (DFS) (hazard ratio [HR] 2.1 [95% CI, 1.36–2.23]; P < 0.001) and OS (HR 1.97 [95% CI, 1.45–2.68]; P < 0.001) in patients 60–69 years of age, but not in those patients who were >70 years of age [32].